-
Risk Factors for Cognitive Impairment in High-Grade Glioma Patients Treated with Postoperative Radiochemotherapy
-
Qiang Wang, Fengxia Xiao, Fei Qi, Xiaopeng Song, Yonghua Yu
-
Cancer Res Treat. 2020;52(2):586-593. Published online December 12, 2019
-
DOI: https://doi.org/10.4143/crt.2019.242
-
-
 Abstract
 PDF PubReader ePub
- Purpose
Fractionated radiotherapy as well as concomitant and adjuvant chemotherapy such as temozolomide for postoperative high-grade glioma (HGG) patients improves progression-free survival and overall survival. Multiple factors such as chemotherapy, radiotherapy, tumor grade, residual tumor volume, and genetic modifications might play a role in the formation of cognitive impairment. The risk factors of cognitive impairment in postoperative patients with HGG receiving radiotherapy and chemotherapy remains a concern in this population. The purpose of this study was to identify risk factors for cognitive impairment in patients of postoperative HGG.
Materials and Methods
A total of 229 patients with HGG who underwent surgery were analyzed. Cognitive impairment was defined as a decrease of Cognitive Assessment Montreal (MoCA)’s score in at least two cognitive domains or any MoCA’s score of less than 26 points at the time of study compared with baseline level. Multiple potential risk factors including methylated status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter, glioma World Health Organization (WHO) grade, residual tumor volume, education, and sex were analyzed. Cox univariate and multivariate regression analysis was used to detect the significant risk factors for cognitive impairment.
Results
At the end of follow-up among the 229 patients, 147 patients (67%) developed cognitive impairment. 82 patients (36%) remained in normal cognitive condition. In multivariate analysis, unmethylated MGMT promoter (hazard ratio [HR], 1.679; 95% confidence interval [CI], 1.212 to 2.326; p=0.002), glioblastoma (HR, 1.550; 95% CI, 1.117 to 2.149; p=0.009), and residual tumor volume > 5.58 cm3 (HR, 1.454; 95% CI, 1.047 to 2.020; p=0.026) were independent risk factors for cognitive impairment.
Conclusion
Methylated status of the MGMT promoter, glioma WHO grade, and residual tumor volume might be risk factors for the cognitive impairment in postoperative patients with HGG.
-
Citations
Citations to this article as recorded by  - The relationship between social participation and cognitive function early after surgery of glioma patients
Yinglian Xiao, Jing Tan, Guo Cheng, Yanhong Deng, Ryota Tamura
PLOS ONE.2025; 20(2): e0319220. CrossRef - Clinical Outcome Assessment Tools for Evaluating the Management of Gliomas
Sachiv Chakravarti, Sneha R. Gupta, Saket Myneni, Mazin Elshareif, James L. Rogers, Chad Caraway, A. Karim Ahmed, Karisa C. Schreck, David O. Kamson, Matthias Holdhoff, Victoria Croog, Kristin J. Redmond, Chetan Bettegowda, Debraj Mukherjee
Cancers.2025; 17(10): 1659. CrossRef - BTK Expression Level Prediction and the High-Grade Glioma Prognosis Using Radiomic Machine Learning Models
Chenggang Jiang, Chen Sun, Xi Wang, Shunchang Ma, Wang Jia, Dainan Zhang
Journal of Imaging Informatics in Medicine.2024; 37(4): 1359. CrossRef - Epigenome-Wide Analysis of DNA Methylation and Optimism in Women and Men
Cuicui Wang, Dawn L. DeMeo, Eric S. Kim, Andres Cardenas, Kelvin C. Fong, Lewina O. Lee, Avron Spiro, Eric A. Whitsel, Steve Horvath, Lifang Hou, Andrea A. Baccarelli, Yun Li, James D. Stewart, JoAnn E. Manson, Francine Grodstein, Laura D. Kubzansky, Joel
Psychosomatic Medicine.2023; 85(1): 89. CrossRef - Factors affecting cognitive functions of patients with high-grade gliomas: a systematic review
Rabeet Tariq, Nowal Hussain, Muhammad Waqas Saeed Baqai
Neurological Sciences.2023; 44(6): 1917. CrossRef - Cognitive functioning in a cohort of high-grade glioma patients
Andreja Cirila Skufca Smrdel, Anja Podlesek, Marija Skoblar Vidmar, Jana Markovic, Jana Jereb, Manja Kuzma Okorn, Uros Smrdel
Radiology and Oncology.2023; 57(2): 201. CrossRef - Cognitive outcomes after multimodal treatment in adult glioma patients: A meta-analysis
Laurien De Roeck, Céline R Gillebert, Robbie C M van Aert, Amber Vanmeenen, Martin Klein, Martin J B Taphoorn, Karin Gehring, Maarten Lambrecht, Charlotte Sleurs
Neuro-Oncology.2023; 25(8): 1395. CrossRef - Factors Associated With Neurocognitive Impairment Following Chemoradiotherapy in Patients With High-Grade Glioma: Results of a Prospective Trial
Prashasti Sharma, Partha Pratim Medhi, Apurba Kumar Kalita, Mouchumee Bhattacharyya, Jyotiman Nath, Gautam Sarma, Yanpothung Yanthan
Brain Tumor Research and Treatment.2023; 11(3): 183. CrossRef - Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner
Yu Cai, Wei Ting Gu, Kang Cheng, Pei Feng Jia, Feng Li, Ming Wang, Wei Feng Zhang, Ji Ting Qiu, Zhe Bao Wu, Wei Guo Zhao
Biochemical and Biophysical Research Communications.2021; 550: 134. CrossRef - Sensitivity of the Montreal Cognitive Assessment in screening for cognitive impairment in patients with newly diagnosed high-grade glioma
Monica Ribeiro, Thomas Durand, Martine Roussel, Loïc Feuvret, Julian Jacob, Dimitri Psimaras, Georges Noel, Audrey Keller, Flavie Bompaire, Khê Hoang-Xuan, Marie-Odile Bernier, Olivier Godefroy, Damien Ricard
Journal of Neuro-Oncology.2020; 148(2): 335. CrossRef
-
7,788
View
-
173
Download
-
14
Web of Science
-
10
Crossref
|
KCA
